Nutrients· 2015Q1
Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts’ Criteria
- 570citations
- Q1SCImago
- 2015year
Short summary
The Salerno Experts' Criteria establish a standardized double-blind, placebo-controlled gluten challenge protocol for diagnosing Non-Celiac Gluten Sensitivity (NCGS), requiring at least a 30% symptom improvement change between gluten and placebo phases.
AI-generated from the title and abstract; the full text is not read.
Key points
- NCGS diagnosis lacks a biomarker, necessitating standardized diagnostic procedures.
- The Salerno Experts' Criteria propose a double-blind, placebo-controlled gluten challenge (8g/day) with a one-week washout.
- A minimum 30% change in 1-3 main symptoms between gluten and placebo challenges is required for diagnosis.
- A self-administered instrument using a modified Gastrointestinal Symptom Rating Scale and Numerical Rating Scale assesses symptom severity.
AI-generated from the title and abstract; the full text is not read.
Abstract
Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis confirmation. In this paper we report experts' recommendations on how the diagnostic protocol should be performed for the confirmation of NCGS. A full diagnostic procedure should assess the clinical response to the gluten-free diet (GFD) and measure the effect of a gluten challenge after a period of treatment with the GFD. The clinical evaluation is performed using a self-administered instrument incorporating a modified version of the Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week challenge followed by a one-week washout of strict GFD and by the crossover to the second one-week challenge. The vehicle should contain cooked, homogeneously distributed gluten. At least a variation of 30% of one to three main symptoms between the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. The guidelines provided in this paper will help the clinician to reach a firm and positive diagnosis of NCGS and facilitate the comparisons of different studies, if adopted internationally.
The authors' abstract, as published at the source. Nutrients, 2015 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Gastroenterology
GastroenterologyMedicine